Jennifer W. Mcvige

Pediatric Neurology

3980 Sheridan Dr
Buffalo, NY 14226

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Proceedings of the 49th Annual Meeting of the American Society of Neuroimaging.

Proceedings of the 49th Annual Meeting of the American Society of Neuroimaging.

Journal: Journal of neuroimaging : official journal of the American Society of Neuroimaging

Published: April 30, 2026

An Occurrence of Mass Psychogenic Illness: LeRoy, New York.

An Occurrence of Mass Psychogenic Illness: LeRoy, New York.

Journal: Journal of child neurology

Published: September 08, 2025

Postural Responses in Trauma-Experienced Individuals.

Postural Responses in Trauma-Experienced Individuals.

Journal: Biomedicines

Published: October 01, 2024

US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review.

US Real-World Effectiveness, Tolerability, and Healthcare Resource Utilization After Addition of Fremanezumab for Preventive Treatment in Patients Using Gepants for Acute Treatment of Migraine: Results From a Retrospective Chart Review.

Journal: Advances in therapy

Published: July 31, 2024

American Headache Society white paper on treatment of post-traumatic headache from concussion in youth.

American Headache Society white paper on treatment of post-traumatic headache from concussion in youth.

Journal: Headache

Published: March 16, 2024

Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials.

Safety and tolerability of atogepant for the preventive treatment of migraine: a post hoc analysis of pooled data from four clinical trials.

Journal: The journal of headache and pain

Published: December 08, 2023

Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open-label, multiple-dose study.

Pharmacokinetics and safety of erenumab in pediatric patients with migraine: A phase I, randomized, open-label, multiple-dose study.

Journal: Clinical and translational science

Published: October 27, 2023

Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.

Real-world persistence and costs among patients with chronic migraine treated with onabotulinumtoxinA or calcitonin gene-related peptide monoclonal antibodies.

Journal: Journal of managed care & specialty pharmacy

Published: September 30, 2023

Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial.

Patient-reported migraine-specific quality of life, activity impairment and headache impact with once-daily atogepant for preventive treatment of migraine in a randomized, 52-week trial.

Journal: Cephalalgia : an international journal of headache

Published: August 28, 2023

Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial.

Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial.

Journal: Cephalalgia : an international journal of headache

Published: January 09, 2023

A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11 years, with an open-label extension.

A multicenter, randomized, double-blind, placebo-controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11 years, with an open-label extension.

Journal: Headache

Published: February 10, 2022

Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine.

Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine.

Journal: Frontiers in neurology

Published: October 01, 2021

Showing 1-12 of 22

Last Updated: 09/26/2026